AU2017339510B2 - Inhibitors of glucocorticoid receptor - Google Patents

Inhibitors of glucocorticoid receptor Download PDF

Info

Publication number
AU2017339510B2
AU2017339510B2 AU2017339510A AU2017339510A AU2017339510B2 AU 2017339510 B2 AU2017339510 B2 AU 2017339510B2 AU 2017339510 A AU2017339510 A AU 2017339510A AU 2017339510 A AU2017339510 A AU 2017339510A AU 2017339510 B2 AU2017339510 B2 AU 2017339510B2
Authority
AU
Australia
Prior art keywords
optionally substituted
alkyl
independently
carbocyclyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017339510A
Other languages
English (en)
Other versions
AU2017339510A1 (en
Inventor
Minna Delarae BALBAS
Xiaohui Du
John Eksterowicz
Valeria R. Fantin
Lawrence R. Mcgee
Julio C. Medina
Yosup Rew
Daqing Sun
Xuelei Yan
Haiying Zhou
Liusheng Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oric Pharmaceuticals Inc
Original Assignee
Oric Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oric Pharmaceuticals Inc filed Critical Oric Pharmaceuticals Inc
Publication of AU2017339510A1 publication Critical patent/AU2017339510A1/en
Application granted granted Critical
Publication of AU2017339510B2 publication Critical patent/AU2017339510B2/en
Priority to AU2020213316A priority Critical patent/AU2020213316B2/en
Priority to AU2021202016A priority patent/AU2021202016C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005Ketals
    • C07J21/008Ketals at position 17
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • C07J71/0015Oxiranes at position 9(11)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017339510A 2016-10-07 2017-10-06 Inhibitors of glucocorticoid receptor Active AU2017339510B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020213316A AU2020213316B2 (en) 2016-10-07 2020-08-05 Inhibitors of glucocorticoid receptor
AU2021202016A AU2021202016C1 (en) 2016-10-07 2021-03-31 Inhibitors of glucocorticoid receptor

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662405801P 2016-10-07 2016-10-07
US62/405,801 2016-10-07
US201762526331P 2017-06-28 2017-06-28
US62/526,331 2017-06-28
PCT/US2017/055660 WO2018068021A1 (en) 2016-10-07 2017-10-06 Inhibitors of glucocorticoid receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020213316A Division AU2020213316B2 (en) 2016-10-07 2020-08-05 Inhibitors of glucocorticoid receptor

Publications (2)

Publication Number Publication Date
AU2017339510A1 AU2017339510A1 (en) 2019-05-23
AU2017339510B2 true AU2017339510B2 (en) 2020-07-30

Family

ID=61832215

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017339510A Active AU2017339510B2 (en) 2016-10-07 2017-10-06 Inhibitors of glucocorticoid receptor
AU2020213316A Active AU2020213316B2 (en) 2016-10-07 2020-08-05 Inhibitors of glucocorticoid receptor
AU2021202016A Active AU2021202016C1 (en) 2016-10-07 2021-03-31 Inhibitors of glucocorticoid receptor

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020213316A Active AU2020213316B2 (en) 2016-10-07 2020-08-05 Inhibitors of glucocorticoid receptor
AU2021202016A Active AU2021202016C1 (en) 2016-10-07 2021-03-31 Inhibitors of glucocorticoid receptor

Country Status (20)

Country Link
US (5) US10472387B2 (OSRAM)
EP (2) EP3523315B1 (OSRAM)
JP (2) JP6801093B2 (OSRAM)
KR (2) KR20210039001A (OSRAM)
CN (2) CN111690031B (OSRAM)
AU (3) AU2017339510B2 (OSRAM)
BR (1) BR112019006987B1 (OSRAM)
CA (1) CA3039636C (OSRAM)
DK (1) DK3523315T3 (OSRAM)
ES (1) ES2867853T3 (OSRAM)
HU (1) HUE054542T2 (OSRAM)
IL (2) IL265835B (OSRAM)
MX (2) MX385658B (OSRAM)
NZ (1) NZ753142A (OSRAM)
PL (1) PL3523315T3 (OSRAM)
PT (1) PT3523315T (OSRAM)
SG (1) SG11201903055UA (OSRAM)
SI (1) SI3523315T1 (OSRAM)
WO (1) WO2018068021A1 (OSRAM)
ZA (1) ZA202004440B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108699102A (zh) 2015-12-23 2018-10-23 欧瑞克制药公司 糖皮质激素受体抑制剂
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
AU2016379417B2 (en) 2015-12-23 2020-09-24 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
DK3523315T3 (da) 2016-10-07 2021-05-03 Oric Pharmaceuticals Inc Inhibitor af glucocorticoidreceptor
EP3773515A4 (en) * 2018-04-11 2022-03-23 Oric Pharmaceuticals, Inc. SOLID FORMS AND FORMULATIONS COMPRISING A GLUCOCORTICOID RECEPTOR ANTAGONIST AND THEIR USES
WO2021163273A1 (en) * 2020-02-12 2021-08-19 Oric Pharmaceuticals, Inc. Uses of glucocorticoid receptor antagonists
US20230212215A1 (en) * 2020-05-08 2023-07-06 Trustees Of Dartmouth College Glucocorticoid receptor modulators
CN115915529A (zh) 2021-09-30 2023-04-04 赛万特科技有限责任公司 发光控制方法、发光控制装置及发光装置
CN114230627B (zh) * 2021-12-31 2023-09-15 湖南新合新生物医药有限公司 一种倍他米松环氧水解物中间体的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405979A (en) * 1990-06-01 1995-04-11 Schering Aktiengesellschaft Process for the production of 10β-H-steroids
US5843933A (en) * 1989-06-23 1998-12-01 Schering Aktiengesellschaft 11β-aryl-4-estrenes, process for their production as well as their use as pharmaceutical agents
US5843931A (en) * 1990-12-22 1998-12-01 Shering Aktiengesellschaft 6,7-modified 11β-aryl-4-oestrenes
CN1222350A (zh) * 1998-01-07 1999-07-14 沈志华 用于大月份引产的复合药物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2528434B1 (fr) 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
JP2785023B2 (ja) 1987-12-30 1998-08-13 ルセル―ユクラフ 17α位置を置換された17β―OH―19―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
JPH02188599A (ja) 1988-11-16 1990-07-24 Roussel Uclaf 3―ケト―デルタ―4,9―19―ノルステロイドから誘導される新物質及びそれらよりなる薬剤
FR2651435A1 (fr) 1989-09-07 1991-03-08 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques.
US5741787A (en) 1993-08-04 1998-04-21 Akzo Nobel N.V. Antiglucocorticoid steroids for the treatment of anxiety disorders
WO1995017192A1 (en) 1993-12-22 1995-06-29 The Salk Institute For Biological Studies Methods for reducing multidrug resistance
SK282570B6 (sk) 1995-02-02 2002-10-08 Schering Aktiengesellschaft Antagonisty progesterónu na výrobu liekov na ošetrenie dysfunkčného maternicového krvácania
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
IL122740A (en) * 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
US6512130B1 (en) * 2000-09-05 2003-01-28 Council Of Scientific And Industrial Research Mifepristone analogue, process for the preparation thereof and use thereof
EP1285927A3 (de) * 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
US7250408B2 (en) * 2002-12-16 2007-07-31 Bayer Schering Pharma Ag Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
DK1989218T3 (da) 2006-02-17 2010-04-26 Janssen Pharmaceutica Nv 17-phosphor-steroidderivater, der er anvendelige som progesteronreceptormodulatorer
MX2008012492A (es) 2006-03-29 2008-12-12 Univ California Compuestos de diariltiohidantoina.
PT2148681E (pt) 2007-04-20 2016-06-17 Preglem Sa Moduladores seletivos da progesterona no tratamento da hemorragia uterina
US8658128B2 (en) 2011-02-03 2014-02-25 Pop Test Cortisol Llc System and method for diagnosis and treatment
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
US20130029953A1 (en) 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
US9289436B2 (en) 2012-02-24 2016-03-22 The University Of Chicago Method of treatment of prostate cancer with androgen receptor and glucocorticoid receptor antagonists
EP2641602A1 (en) 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
US9096641B2 (en) * 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
CA2933590C (en) * 2013-12-11 2023-10-03 Sloan-Kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
CN108699102A (zh) * 2015-12-23 2018-10-23 欧瑞克制药公司 糖皮质激素受体抑制剂
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
AU2016379417B2 (en) 2015-12-23 2020-09-24 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
DK3523315T3 (da) 2016-10-07 2021-05-03 Oric Pharmaceuticals Inc Inhibitor af glucocorticoidreceptor
US12233073B2 (en) 2017-06-09 2025-02-25 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
EP3773515A4 (en) 2018-04-11 2022-03-23 Oric Pharmaceuticals, Inc. SOLID FORMS AND FORMULATIONS COMPRISING A GLUCOCORTICOID RECEPTOR ANTAGONIST AND THEIR USES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843933A (en) * 1989-06-23 1998-12-01 Schering Aktiengesellschaft 11β-aryl-4-estrenes, process for their production as well as their use as pharmaceutical agents
US5405979A (en) * 1990-06-01 1995-04-11 Schering Aktiengesellschaft Process for the production of 10β-H-steroids
US5843931A (en) * 1990-12-22 1998-12-01 Shering Aktiengesellschaft 6,7-modified 11β-aryl-4-oestrenes
CN1222350A (zh) * 1998-01-07 1999-07-14 沈志华 用于大月份引产的复合药物

Also Published As

Publication number Publication date
DK3523315T3 (da) 2021-05-03
IL265835B (en) 2021-06-30
PL3523315T3 (pl) 2021-10-18
AU2021202016B2 (en) 2022-01-06
EP3851444A1 (en) 2021-07-21
SG11201903055UA (en) 2019-05-30
AU2017339510A1 (en) 2019-05-23
CN111690031B (zh) 2021-06-01
HUE054542T2 (hu) 2021-09-28
BR112019006987A2 (pt) 2019-06-25
EP3523315A4 (en) 2020-04-15
KR20210039001A (ko) 2021-04-08
JP2021046409A (ja) 2021-03-25
CA3039636C (en) 2023-04-11
EP3523315B1 (en) 2021-03-24
IL265835A (en) 2019-06-30
US20200055892A1 (en) 2020-02-20
US20210017219A1 (en) 2021-01-21
BR112019006987B1 (pt) 2021-05-04
KR20190083651A (ko) 2019-07-12
CN110099915A (zh) 2019-08-06
PT3523315T (pt) 2021-04-29
CA3039636A1 (en) 2018-04-12
AU2020213316B2 (en) 2021-03-11
MX2021010252A (es) 2021-09-21
WO2018068021A1 (en) 2018-04-12
SI3523315T1 (sl) 2021-08-31
US20200291058A1 (en) 2020-09-17
AU2021202016A1 (en) 2021-04-29
EP3523315A1 (en) 2019-08-14
ES2867853T3 (es) 2021-10-21
US20230096870A1 (en) 2023-03-30
US20190218246A1 (en) 2019-07-18
KR102237916B1 (ko) 2021-04-09
AU2021202016C1 (en) 2022-06-09
CN111690031A (zh) 2020-09-22
ZA202004440B (en) 2022-07-27
US10723759B2 (en) 2020-07-28
US10472387B2 (en) 2019-11-12
AU2020213316A1 (en) 2020-08-27
NZ753142A (en) 2020-08-28
IL284005A (en) 2021-07-29
JP2019533651A (ja) 2019-11-21
US10836789B2 (en) 2020-11-17
MX2019004030A (es) 2019-09-16
MX385658B (es) 2025-03-18
JP6801093B2 (ja) 2020-12-16

Similar Documents

Publication Publication Date Title
AU2021202016C1 (en) Inhibitors of glucocorticoid receptor
AU2021202019B2 (en) Inhibitors of glucocorticoid receptor
AU2020256460A1 (en) Inhibitors of glucocorticoid receptor
WO2017112904A1 (en) Inhibitors of glucocorticoid receptor
HK40053917A (en) Inhibitors of glucocorticoid receptor
EA041590B1 (ru) Ингибиторы глюкокортикоидного рецептора

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 JUL 2020

FGA Letters patent sealed or granted (standard patent)